{
  "input": {
    "mode": "score",
    "query": {
      "entity": "Generalised pustular psoriasis",
      "relation": "indication"
    },
    "hypotheses": [
      {
        "id": "H1",
        "candidate": {
          "id": "drug_acitretin",
          "name": "Acitretin"
        }
      },
      {
        "id": "H2",
        "candidate": {
          "id": "drug_adalimumab",
          "name": "Adalimumab"
        }
      },
      {
        "id": "H3",
        "candidate": {
          "id": "drug_etanercept",
          "name": "Etanercept"
        }
      },
      {
        "id": "H4",
        "candidate": {
          "id": "drug_infliximab",
          "name": "Infliximab"
        }
      },
      {
        "id": "H5",
        "candidate": {
          "id": "drug_methotrexate",
          "name": "Methotrexate"
        }
      },
      {
        "id": "H6",
        "candidate": {
          "id": "drug_omalizumab",
          "name": "Omalizumab"
        }
      },
      {
        "id": "H7",
        "candidate": {
          "id": "drug_secukinumab",
          "name": "Secukinumab"
        }
      },
      {
        "id": "H8",
        "candidate": {
          "id": "drug_ustekinumab",
          "name": "Ustekinumab"
        }
      },
      {
        "id": "H9",
        "candidate": {
          "id": "drug_brodalumab",
          "name": "Brodalumab"
        }
      },
      {
        "id": "H10",
        "candidate": {
          "id": "drug_apremilast",
          "name": "Apremilast"
        }
      },
      {
        "id": "H11",
        "candidate": {
          "id": "drug_tildrakizumab",
          "name": "Tildrakizumab"
        }
      },
      {
        "id": "H12",
        "candidate": {
          "id": "drug_guselkumab",
          "name": "Guselkumab"
        }
      }
    ],
    "tegraph_snapshot": {
      "nodes": [
        {
          "id": "drug_acitretin",
          "type": "Drug",
          "label": "Acitretin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_adalimumab",
          "type": "Drug",
          "label": "Adalimumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_etanercept",
          "type": "Drug",
          "label": "Etanercept",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_infliximab",
          "type": "Drug",
          "label": "Infliximab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_omalizumab",
          "type": "Drug",
          "label": "Omalizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_secukinumab",
          "type": "Drug",
          "label": "Secukinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_brodalumab",
          "type": "Drug",
          "label": "Brodalumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_apremilast",
          "type": "Drug",
          "label": "Apremilast",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_tildrakizumab",
          "type": "Drug",
          "label": "Tildrakizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_guselkumab",
          "type": "Drug",
          "label": "Guselkumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "target_TNF",
          "type": "Target",
          "label": "TNF",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "target_IL17",
          "type": "Target",
          "label": "IL-17",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "pathway_inflammatory_response",
          "type": "Pathway",
          "label": "Inflammatory Response Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "disease_generalised_pustular_psoriasis",
          "type": "Disease",
          "label": "Generalised Pustular Psoriasis",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_ot_acitretin",
          "type": "Target",
          "label": "OffTarget_Acitretin",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_acitretin",
          "type": "Pathway",
          "label": "RiskPathway_Acitretin",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_acitretin",
          "type": "Phenotype",
          "label": "AdversePhenotype_Acitretin",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_adalimumab",
          "type": "Target",
          "label": "OffTarget_Adalimumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_adalimumab",
          "type": "Pathway",
          "label": "RiskPathway_Adalimumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_adalimumab",
          "type": "Phenotype",
          "label": "AdversePhenotype_Adalimumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_etanercept",
          "type": "Target",
          "label": "OffTarget_Etanercept",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_etanercept",
          "type": "Pathway",
          "label": "RiskPathway_Etanercept",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_etanercept",
          "type": "Phenotype",
          "label": "AdversePhenotype_Etanercept",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_infliximab",
          "type": "Target",
          "label": "OffTarget_Infliximab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_infliximab",
          "type": "Pathway",
          "label": "RiskPathway_Infliximab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_infliximab",
          "type": "Phenotype",
          "label": "AdversePhenotype_Infliximab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_methotrexate",
          "type": "Target",
          "label": "OffTarget_Methotrexate",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_methotrexate",
          "type": "Pathway",
          "label": "RiskPathway_Methotrexate",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_methotrexate",
          "type": "Phenotype",
          "label": "AdversePhenotype_Methotrexate",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_omalizumab",
          "type": "Target",
          "label": "OffTarget_Omalizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_omalizumab",
          "type": "Pathway",
          "label": "RiskPathway_Omalizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_omalizumab",
          "type": "Phenotype",
          "label": "AdversePhenotype_Omalizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_secukinumab",
          "type": "Target",
          "label": "OffTarget_Secukinumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_secukinumab",
          "type": "Pathway",
          "label": "RiskPathway_Secukinumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_secukinumab",
          "type": "Phenotype",
          "label": "AdversePhenotype_Secukinumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_ustekinumab",
          "type": "Target",
          "label": "OffTarget_Ustekinumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_ustekinumab",
          "type": "Pathway",
          "label": "RiskPathway_Ustekinumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_ustekinumab",
          "type": "Phenotype",
          "label": "AdversePhenotype_Ustekinumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_brodalumab",
          "type": "Target",
          "label": "OffTarget_Brodalumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_brodalumab",
          "type": "Pathway",
          "label": "RiskPathway_Brodalumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_brodalumab",
          "type": "Phenotype",
          "label": "AdversePhenotype_Brodalumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_apremilast",
          "type": "Target",
          "label": "OffTarget_Apremilast",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_apremilast",
          "type": "Pathway",
          "label": "RiskPathway_Apremilast",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_apremilast",
          "type": "Phenotype",
          "label": "AdversePhenotype_Apremilast",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_tildrakizumab",
          "type": "Target",
          "label": "OffTarget_Tildrakizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_tildrakizumab",
          "type": "Pathway",
          "label": "RiskPathway_Tildrakizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_tildrakizumab",
          "type": "Phenotype",
          "label": "AdversePhenotype_Tildrakizumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_guselkumab",
          "type": "Target",
          "label": "OffTarget_Guselkumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_guselkumab",
          "type": "Pathway",
          "label": "RiskPathway_Guselkumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_guselkumab",
          "type": "Phenotype",
          "label": "AdversePhenotype_Guselkumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "H1",
          "type": "Hypothesis",
          "label": "Acitretin",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H2",
          "type": "Hypothesis",
          "label": "Adalimumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H3",
          "type": "Hypothesis",
          "label": "Etanercept",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H4",
          "type": "Hypothesis",
          "label": "Infliximab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H5",
          "type": "Hypothesis",
          "label": "Methotrexate",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H6",
          "type": "Hypothesis",
          "label": "Omalizumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H7",
          "type": "Hypothesis",
          "label": "Secukinumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H8",
          "type": "Hypothesis",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H9",
          "type": "Hypothesis",
          "label": "Brodalumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H10",
          "type": "Hypothesis",
          "label": "Apremilast",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H11",
          "type": "Hypothesis",
          "label": "Tildrakizumab",
          "attrs": {
            "agent": "PI"
          }
        },
        {
          "id": "H12",
          "type": "Hypothesis",
          "label": "Guselkumab",
          "attrs": {
            "agent": "PI"
          }
        }
      ],
      "edges": [
        {
          "source": "drug_acitretin",
          "target": "target_TNF",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "Acitretin的已知机制作用于TNF通路"
        },
        {
          "source": "drug_adalimumab",
          "target": "target_TNF",
          "relation": "acts_on",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "Adalimumab靶向TNF，适用于炎症性疾病"
        },
        {
          "source": "drug_etanercept",
          "target": "target_TNF",
          "relation": "acts_on",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "Etanercept作为TNF拮抗剂"
        },
        {
          "source": "drug_infliximab",
          "target": "target_TNF",
          "relation": "acts_on",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "Infliximab通过抑制TNF治疗多种皮肤病"
        },
        {
          "source": "drug_methotrexate",
          "target": "target_TNF",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Methotrexate可以降低TNF水平"
        },
        {
          "source": "drug_secukinumab",
          "target": "target_IL17",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "Secukinumab特异性靶向IL-17"
        },
        {
          "source": "drug_ustekinumab",
          "target": "target_IL17",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Ustekinumab作用于IL-12和IL-23相关通路"
        },
        {
          "source": "drug_brodalumab",
          "target": "target_IL17",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "Brodalumab通过抑制IL-17实现治疗"
        },
        {
          "source": "drug_apremilast",
          "target": "pathway_inflammatory_response",
          "relation": "modulates",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "Apremilast对炎症通路的调节作用"
        },
        {
          "source": "drug_tildrakizumab",
          "target": "target_IL17",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Tildrakizumab作为IL-23抑制剂"
        },
        {
          "source": "drug_guselkumab",
          "target": "target_IL17",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Guselkumab通过IL-23靶向作用"
        },
        {
          "source": "drug_acitretin",
          "target": "n_ot_acitretin",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "存在可能的离靶作用"
        },
        {
          "source": "n_ot_acitretin",
          "target": "n_rp_acitretin",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能引发相关风险通路"
        },
        {
          "source": "n_rp_acitretin",
          "target": "n_adv_acitretin",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可导致不良表型"
        },
        {
          "source": "n_adv_acitretin",
          "target": "H1",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若风险成立，将抵消治疗益处"
        },
        {
          "source": "drug_adalimumab",
          "target": "n_ot_adalimumab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "存在可能的离靶作用"
        },
        {
          "source": "n_ot_adalimumab",
          "target": "n_rp_adalimumab",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能引发相关风险通路"
        },
        {
          "source": "n_rp_adalimumab",
          "target": "n_adv_adalimumab",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可导致不良表型"
        },
        {
          "source": "n_adv_adalimumab",
          "target": "H2",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若风险成立，将抵消治疗益处"
        },
        {
          "source": "drug_etanercept",
          "target": "n_ot_etanercept",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "存在可能的离靶作用"
        },
        {
          "source": "n_ot_etanercept",
          "target": "n_rp_etanercept",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能引发相关风险通路"
        },
        {
          "source": "n_rp_etanercept",
          "target": "n_adv_etanercept",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可导致不良表型"
        },
        {
          "source": "n_adv_etanercept",
          "target": "H3",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若风险成立，将抵消治疗益处"
        },
        {
          "source": "drug_infliximab",
          "target": "n_ot_infliximab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "存在可能的离靶作用"
        },
        {
          "source": "n_ot_infliximab",
          "target": "n_rp_infliximab",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能引发相关风险通路"
        },
        {
          "source": "n_rp_infliximab",
          "target": "n_adv_infliximab",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可导致不良表型"
        },
        {
          "source": "n_adv_infliximab",
          "target": "H4",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若风险成立，将抵消治疗益处"
        },
        {
          "source": "drug_methotrexate",
          "target": "n_ot_methotrexate",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "存在可能的离靶作用"
        },
        {
          "source": "n_ot_methotrexate",
          "target": "n_rp_methotrexate",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能引发相关风险通路"
        },
        {
          "source": "n_rp_methotrexate",
          "target": "n_adv_methotrexate",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可导致不良表型"
        },
        {
          "source": "n_adv_methotrexate",
          "target": "H5",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若风险成立，将抵消治疗益处"
        },
        {
          "source": "drug_omalizumab",
          "target": "n_ot_omalizumab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "存在可能的离靶作用"
        },
        {
          "source": "n_ot_omalizumab",
          "target": "n_rp_omalizumab",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能引发相关风险通路"
        },
        {
          "source": "n_rp_omalizumab",
          "target": "n_adv_omalizumab",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可导致不良表型"
        },
        {
          "source": "n_adv_omalizumab",
          "target": "H6",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若风险成立，将抵消治疗益处"
        },
        {
          "source": "drug_secukinumab",
          "target": "n_ot_secukinumab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "存在可能的离靶作用"
        },
        {
          "source": "n_ot_secukinumab",
          "target": "n_rp_secukinumab",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能引发相关风险通路"
        },
        {
          "source": "n_rp_secukinumab",
          "target": "n_adv_secukinumab",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可导致不良表型"
        },
        {
          "source": "n_adv_secukinumab",
          "target": "H7",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若风险成立，将抵消治疗益处"
        },
        {
          "source": "drug_ustekinumab",
          "target": "n_ot_ustekinumab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "存在可能的离靶作用"
        },
        {
          "source": "n_ot_ustekinumab",
          "target": "n_rp_ustekinumab",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能引发相关风险通路"
        },
        {
          "source": "n_rp_ustekinumab",
          "target": "n_adv_ustekinumab",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可导致不良表型"
        },
        {
          "source": "n_adv_ustekinumab",
          "target": "H8",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若风险成立，将抵消治疗益处"
        },
        {
          "source": "drug_brodalumab",
          "target": "n_ot_brodalumab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "存在可能的离靶作用"
        },
        {
          "source": "n_ot_brodalumab",
          "target": "n_rp_brodalumab",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能引发相关风险通路"
        },
        {
          "source": "n_rp_brodalumab",
          "target": "n_adv_brodalumab",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可导致不良表型"
        },
        {
          "source": "n_adv_brodalumab",
          "target": "H9",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若风险成立，将抵消治疗益处"
        },
        {
          "source": "drug_apremilast",
          "target": "n_ot_apremilast",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "存在可能的离靶作用"
        },
        {
          "source": "n_ot_apremilast",
          "target": "n_rp_apremilast",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能引发相关风险通路"
        },
        {
          "source": "n_rp_apremilast",
          "target": "n_adv_apremilast",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可导致不良表型"
        },
        {
          "source": "n_adv_apremilast",
          "target": "H10",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若风险成立，将抵消治疗益处"
        },
        {
          "source": "drug_tildrakizumab",
          "target": "n_ot_tildrakizumab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "存在可能的离靶作用"
        },
        {
          "source": "n_ot_tildrakizumab",
          "target": "n_rp_tildrakizumab",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能引发相关风险通路"
        },
        {
          "source": "n_rp_tildrakizumab",
          "target": "n_adv_tildrakizumab",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可导致不良表型"
        },
        {
          "source": "n_adv_tildrakizumab",
          "target": "H11",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若风险成立，将抵消治疗益处"
        },
        {
          "source": "drug_guselkumab",
          "target": "n_ot_guselkumab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "存在可能的离靶作用"
        },
        {
          "source": "n_ot_guselkumab",
          "target": "n_rp_guselkumab",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能引发相关风险通路"
        },
        {
          "source": "n_rp_guselkumab",
          "target": "n_adv_guselkumab",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可导致不良表型"
        },
        {
          "source": "n_adv_guselkumab",
          "target": "H12",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "若风险成立，将抵消治疗益处"
        }
      ],
      "round_index": 1
    },
    "history": {
      "round": 1,
      "last_scores": []
    },
    "thresholds": {
      "stop_delta": 0.03,
      "saturation_ratio": 0.65,
      "weights": {
        "path_disjointness": 1.0
      }
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "scoring_summary": [
      {
        "hypothesis_id": "H1",
        "score": 0.52,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.6,
          "indication_plausibility": 0.5,
          "safety_risk": 0.2,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.17
        },
        "graph_signals": {
          "support_weight": 0.8,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": true,
          "path_disjointness": 0,
          "conflict_hotspots": [
            {
              "topic": "Risk of adverse effects related to off-target actions",
              "pro": [
                "drug_acitretin"
              ],
              "con": [
                "n_adv_acitretin"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Acitretin acts on TNF pathway, relevant for treatment."
          ],
          "safety_risk": [
            "Potential adverse effects due to off-target actions."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Further validation of adverse effects and off-target actions needed."
        ]
      },
      {
        "hypothesis_id": "H2",
        "score": 0.54,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.6,
          "indication_plausibility": 0.5,
          "safety_risk": 0.2,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.17
        },
        "graph_signals": {
          "support_weight": 0.8,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": true,
          "path_disjointness": 0,
          "conflict_hotspots": [
            {
              "topic": "Risk of adverse effects related to off-target actions",
              "pro": [
                "drug_adalimumab"
              ],
              "con": [
                "n_adv_adalimumab"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Adalimumab targets TNF, suitable for inflammatory diseases."
          ],
          "safety_risk": [
            "Potential adverse effects due to off-target actions."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Further validation of adverse effects and off-target actions needed."
        ]
      },
      {
        "hypothesis_id": "H3",
        "score": 0.54,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.6,
          "indication_plausibility": 0.5,
          "safety_risk": 0.2,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.17
        },
        "graph_signals": {
          "support_weight": 0.8,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": true,
          "path_disjointness": 0,
          "conflict_hotspots": [
            {
              "topic": "Risk of adverse effects related to off-target actions",
              "pro": [
                "drug_etanercept"
              ],
              "con": [
                "n_adv_etanercept"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Etanercept is a TNF antagonist."
          ],
          "safety_risk": [
            "Potential adverse effects due to off-target actions."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Further validation of adverse effects and off-target actions needed."
        ]
      },
      {
        "hypothesis_id": "H4",
        "score": 0.54,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.6,
          "indication_plausibility": 0.5,
          "safety_risk": 0.2,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.17
        },
        "graph_signals": {
          "support_weight": 0.8,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": true,
          "path_disjointness": 0,
          "conflict_hotspots": [
            {
              "topic": "Risk of adverse effects related to off-target actions",
              "pro": [
                "drug_infliximab"
              ],
              "con": [
                "n_adv_infliximab"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Infliximab suppresses TNF for skin diseases."
          ],
          "safety_risk": [
            "Potential adverse effects due to off-target actions."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Further validation of adverse effects and off-target actions needed."
        ]
      },
      {
        "hypothesis_id": "H5",
        "score": 0.52,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.6,
          "indication_plausibility": 0.5,
          "safety_risk": 0.2,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.17
        },
        "graph_signals": {
          "support_weight": 0.8,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": true,
          "path_disjointness": 0,
          "conflict_hotspots": [
            {
              "topic": "Risk of adverse effects related to off-target actions",
              "pro": [
                "drug_methotrexate"
              ],
              "con": [
                "n_adv_methotrexate"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Methotrexate can reduce TNF levels."
          ],
          "safety_risk": [
            "Potential adverse effects due to off-target actions."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Further validation of adverse effects and off-target actions needed."
        ]
      },
      {
        "hypothesis_id": "H6",
        "score": 0.52,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.6,
          "indication_plausibility": 0.5,
          "safety_risk": 0.2,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.17
        },
        "graph_signals": {
          "support_weight": 0.8,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": true,
          "path_disjointness": 0,
          "conflict_hotspots": [
            {
              "topic": "Risk of adverse effects related to off-target actions",
              "pro": [
                "drug_omalizumab"
              ],
              "con": [
                "n_adv_omalizumab"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Omalizumab's role needs better elucidation for psoriasis."
          ],
          "safety_risk": [
            "Potential adverse effects due to off-target actions."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Further validation of adverse effects and off-target actions needed."
        ]
      },
      {
        "hypothesis_id": "H7",
        "score": 0.52,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.6,
          "indication_plausibility": 0.5,
          "safety_risk": 0.2,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.17
        },
        "graph_signals": {
          "support_weight": 0.8,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": true,
          "path_disjointness": 0,
          "conflict_hotspots": [
            {
              "topic": "Risk of adverse effects related to off-target actions",
              "pro": [
                "drug_secukinumab"
              ],
              "con": [
                "n_adv_secukinumab"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Secukinumab specifically targets IL-17."
          ],
          "safety_risk": [
            "Potential adverse effects due to off-target actions."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Further validation of adverse effects and off-target actions needed."
        ]
      },
      {
        "hypothesis_id": "H8",
        "score": 0.52,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.6,
          "indication_plausibility": 0.5,
          "safety_risk": 0.2,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.17
        },
        "graph_signals": {
          "support_weight": 0.8,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": true,
          "path_disjointness": 0,
          "conflict_hotspots": [
            {
              "topic": "Risk of adverse effects related to off-target actions",
              "pro": [
                "drug_ustekinumab"
              ],
              "con": [
                "n_adv_ustekinumab"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Ustekinumab acts on IL-12 and IL-23 pathways."
          ],
          "safety_risk": [
            "Potential adverse effects due to off-target actions."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Further validation of adverse effects and off-target actions needed."
        ]
      },
      {
        "hypothesis_id": "H9",
        "score": 0.52,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.6,
          "indication_plausibility": 0.5,
          "safety_risk": 0.2,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.17
        },
        "graph_signals": {
          "support_weight": 0.8,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": true,
          "path_disjointness": 0,
          "conflict_hotspots": [
            {
              "topic": "Risk of adverse effects related to off-target actions",
              "pro": [
                "drug_brodalumab"
              ],
              "con": [
                "n_adv_brodalumab"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Brodalumab acts by inhibiting IL-17."
          ],
          "safety_risk": [
            "Potential adverse effects due to off-target actions."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Further validation of adverse effects and off-target actions needed."
        ]
      },
      {
        "hypothesis_id": "H10",
        "score": 0.52,
        "components": {
          "mechanism_fit": 0.6,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.6,
          "indication_plausibility": 0.5,
          "safety_risk": 0.2,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.17
        },
        "graph_signals": {
          "support_weight": 0.6,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": false,
          "path_disjointness": 0,
          "conflict_hotspots": [
            {
              "topic": "Risk of adverse effects related to off-target actions",
              "pro": [
                "drug_apremilast"
              ],
              "con": [
                "n_adv_apremilast"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Apremilast modulates inflammatory pathways."
          ],
          "safety_risk": [
            "Potential adverse effects due to off-target actions."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Further validation of adverse effects and off-target actions needed."
        ]
      },
      {
        "hypothesis_id": "H11",
        "score": 0.52,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.6,
          "indication_plausibility": 0.5,
          "safety_risk": 0.2,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.17
        },
        "graph_signals": {
          "support_weight": 0.8,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": true,
          "path_disjointness": 0,
          "conflict_hotspots": [
            {
              "topic": "Risk of adverse effects related to off-target actions",
              "pro": [
                "drug_tildrakizumab"
              ],
              "con": [
                "n_adv_tildrakizumab"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Tildrakizumab inhibits IL-23."
          ],
          "safety_risk": [
            "Potential adverse effects due to off-target actions."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Further validation of adverse effects and off-target actions needed."
        ]
      },
      {
        "hypothesis_id": "H12",
        "score": 0.52,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.6,
          "indication_plausibility": 0.5,
          "safety_risk": 0.2,
          "graph_bonus": 0.1,
          "conflict_penalty": 0.17
        },
        "graph_signals": {
          "support_weight": 0.8,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": true,
          "path_disjointness": 0,
          "conflict_hotspots": [
            {
              "topic": "Risk of adverse effects related to off-target actions",
              "pro": [
                "drug_guselkumab"
              ],
              "con": [
                "n_adv_guselkumab"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Guselkumab acts through IL-23 targeting."
          ],
          "safety_risk": [
            "Potential adverse effects due to off-target actions."
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Further validation of adverse effects and off-target actions needed."
        ]
      }
    ],
    "ranking": [
      "H2",
      "H3",
      "H4",
      "H1",
      "H5",
      "H6",
      "H7",
      "H8",
      "H9",
      "H10",
      "H11",
      "H12"
    ],
    "delta_since_last_round": 0.06,
    "stop_decision": {
      "should_stop": false,
      "reasons": [
        "Δscore≥0.03"
      ]
    }
  }
}